Last Updated: November 16, 2026

Details for Patent: 7,323,195

« Back to Dashboard


Summary for Patent: 7,323,195
Title:Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
Abstract:Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a formulation of a proanthocyanidin polymer composition which protects the composition from the effects of stomach acid after oral administration, particularly to those formulations which are enteric coated. The invention also relates to methods of producing a directly compressible proanthocyanidin polymer composition, as well as compositions containing the directly compressible proanthocyanidin polymer composition.
Inventor(s):Edward James Rozhon, Atul S. Khandwala, Akram Sabouni, Gul P. Balwani, Jody Wai-Han Chan, David F. Sesin
Assignee: Napo Pharmaceuticals Inc
Application Number:US10/919,969
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;
Patent landscape, scope, and claims:

United States Patent 7,323,195: Scope, Claims, Expiration, and Crofelemer Patent Landscape

U.S. Patent No. 7,323,195 protects oral pharmaceutical compositions containing an aqueous-soluble, isolated proanthocyanidin polymer derived from Croton or Calophyllum species, when formulated to shield the polymer from the stomach environment. The patent is most closely associated with crofelemer, the proanthocyanidin polymer derived from Croton lechleri and marketed in the United States as Mytesi.

The patent issued on January 29, 2008, and its public patent record identifies a May 11, 2001 priority date. The patent’s listed term ended May 11, 2022. It is therefore expired and no longer presents a current U.S. patent barrier to an otherwise lawful generic formulation. Its historical significance remains relevant because it covered the oral delayed-release formulation architecture used for crofelemer products. (U.S. Patent No. 7,323,195, 2008; U.S. Food and Drug Administration [FDA], n.d.-a)

What does U.S. Patent 7,323,195 protect?

The patent protects pharmaceutical compositions rather than the Croton lechleri plant, the botanical extraction process, or crofelemer as a chemical entity in every possible form.

Its principal technical requirement is that the proanthocyanidin polymer be:

  1. Isolated;
  2. Aqueous soluble;
  3. Derived from Croton or Calophyllum species; and
  4. Formulated to avoid exposure to the stomach environment.

Claim 1 requires an enteric-coated composition. Claim 2 covers a controlled-release oral preparation that protects the polymer from the stomach. The dependent claims narrow the scope by specifying the botanical source, coating chemistry, dosage form, bead structure, lubricant, and physical presentation.

The commercial relevance is strongest for crofelemer, which is derived from Croton lechleri. The patent does not, however, limit all independent claim scope to Croton lechleri. Claims 1 and 2 also cover qualifying polymers from other Croton species and from Calophyllum species.

How many independent claims does Patent 7,323,195 have?

The patent has two independent composition claims:

Claim Independent requirement Main formulation concept
1 Aqueous-soluble isolated proanthocyanidin polymer from Croton or Calophyllum, enteric coated, with carrier Enteric protection
2 Aqueous-soluble isolated proanthocyanidin polymer from Croton or Calophyllum, protected from stomach environment in controlled-release oral preparation, with carrier Controlled release

Claims 3 through 12 depend on claims 1, 2, or 9 and add narrower limitations.

Claim 1 is the more specific independent claim because it expressly requires an enteric coating. Claim 2 is structurally different. It requires a controlled-release preparation that protects the polymer from the stomach but does not expressly require the particular enteric-coating language used in claim 1.

What are the key limitations in Claim 1?

Claim 1 requires every element below:

Claim element Scope implication
Pharmaceutical composition The claim is directed to a finished dosage composition, not merely an extract
Aqueous-soluble isolated proanthocyanidin polymer composition The active material must satisfy both isolation and aqueous-solubility requirements
From a Croton spp. or Calophyllum spp. The botanical source is material; synthetic or unrelated tannin polymers would fall outside this limitation
Formulated with an enteric coating The dosage form must have a stomach-resistant coating
Protect the polymer composition from the stomach environment The coating must perform a functional gastrointestinal-protection role
Pharmaceutically acceptable carrier A finished pharmaceutical formulation is required

The source limitation is broader than Croton lechleri. Claim 3 narrows claim 1 to Croton lechleri, but a competing composition could potentially fall within claim 1 without satisfying claim 3 if it uses another qualifying Croton species or a qualifying Calophyllum species.

The phrase “aqueous soluble” is important. A composition containing an insoluble botanical fraction would present a claim-scope issue even if it originated from Croton lechleri. Likewise, a formulation containing crofelemer but using a materially different active fraction could raise questions concerning whether it is the same isolated proanthocyanidin polymer composition.

What are the key limitations in Claim 2?

Claim 2 covers an oral controlled-release preparation designed to protect the polymer from the stomach environment. It does not use the same express “enteric coating” requirement as claim 1.

This creates two distinct design-around and infringement questions:

  1. Whether a delayed-release system that protects the active ingredient through the stomach is an enteric formulation under claim 1.
  2. Whether the same system independently satisfies claim 2 because it is a controlled-release oral preparation that protects the polymer from the stomach.

A formulation could be outside claim 1 if it lacks an enteric coating but still face claim 2 if it uses another mechanism that provides controlled release and stomach protection. Conversely, an enteric-coated immediate-release product could implicate claim 1 without necessarily meeting every controlled-release requirement of claim 2.

Claim 4 narrows claim 2 to Croton lechleri.

What formulations are protected by the dependent claims?

The dependent claims target common oral dosage-form implementations.

Claim Added limitation Commercial interpretation
3 Croton species is Croton lechleri Crofelemer-source embodiment under claim 1
4 Croton species is Croton lechleri Crofelemer-source embodiment under claim 2
5 Methacrylic acid-methacrylic acid ester copolymer with acid-ionizable groups Enteric polymer coating, consistent with methacrylate-based systems
6 Compressed tablet Tablet dosage form
7 Enteric-coated capsule Capsule shell or capsule dosage form with enteric protection
8 Capsule containing beads with polymer core and enteric layer Multiparticulate or pelletized delivery system
9 Lubricant added to claim 1 formulation Manufacturing and tableting aid
10 Lubricant added to claim 2 formulation Manufacturing and controlled-release formulation aid
11 Lubricant is magnesium stearate Specific lubricant limitation
12 Enteric-coated granules or powder Multiparticulate or powder-based oral formulation

Claim 8 is technically significant because it covers a capsule containing multiple coated beads rather than a single coated tablet or capsule. A bead-based product would need to be analyzed at the particle level: each bead must have a proanthocyanidin polymer core and an enteric-coating layer.

Claim 12 covers enteric-coated granules or powder. It is narrower than the broad composition claim because it specifies the physical form of the active formulation.

The dependent claims do not independently protect the coating material, magnesium stearate, tablet compression, or capsule technology in the abstract. Those features are protected only when combined with the active polymer composition and other limitations inherited from the relevant parent claim.

When did U.S. Patent 7,323,195 expire?

The patent’s listed expiration date was May 11, 2022.

Milestone Date
Earliest identified priority date May 11, 2001
Patent issued January 29, 2008
Listed U.S. patent expiration May 11, 2022
Current status Expired

The expiration removes ordinary patent-enforcement rights for the claimed U.S. composition subject matter. It does not eliminate other possible rights involving later patents, trademarks, regulatory exclusivity, trade secrets, manufacturing know-how, or patents covering different methods of use or formulations.

Patent expiration also does not automatically establish that a proposed generic product is approvable. An ANDA applicant would still need to address active-ingredient identity, product quality, bioequivalence, manufacturing controls, and any separately listed patents or exclusivities applicable to the relevant reference product.

What is the Orange Book status of Patent 7,323,195?

Patent 7,323,195 was associated with the U.S. crofelemer product Fulyzaq, later marketed as Mytesi. The FDA Orange Book identified the patent with a May 11, 2022 expiration date. The patent’s practical Orange Book significance ended when that date passed. (FDA, n.d.-a)

The patent was a formulation patent. It was not a method-of-use patent directed solely to treatment of a particular patient population. That distinction matters because an ANDA applicant generally addresses listed patents through the applicable certification framework, while a labeling carve-out may be relevant for method-of-use patents.

The Orange Book status should be evaluated at the product level because the same active ingredient can be associated with different NDA holders, dosage forms, patent listings, and regulatory supplements.

Were there Paragraph IV challenges to Patent 7,323,195?

No publicly documented, commercially significant Paragraph IV challenge to Patent 7,323,195 is identified in the cited public FDA and patent records.

The absence of a known reported challenge does not imply that the patent was never considered by a potential ANDA applicant. The patent expired before a public generic challenge became a central commercial issue. That timing reduced the value of a Paragraph IV litigation strategy because a challenger could wait for expiration rather than incur the cost and risk of an early-entry dispute.

For a generic applicant today, the key issue is not whether to challenge Patent 7,323,195. The patent is expired. The relevant questions are whether later patents remain listed, whether the proposed product uses the same active ingredient and release profile, and whether the applicant can obtain approval through the appropriate FDA pathway.

What patent litigation affects crofelemer?

Patent 7,323,195 does not present a current litigation barrier because it expired in 2022. No major reported U.S. litigation outcome involving this patent is identified in the cited public records.

Potential litigation exposure for a crofelemer product could instead arise from:

  • Later formulation patents;
  • Method-of-use patents covering diarrhea associated with specific diseases or treatments;
  • Patents covering manufacturing, purification, standardization, or dosage-form production;
  • Contractual disputes involving licensed botanical materials or commercial rights;
  • Regulatory exclusivity or labeling disputes unrelated to the expired patent.

The patent itself has limited current litigation value. Its historical value was greater during the period when an enteric or controlled-release crofelemer formulation needed to be commercialized before expiration.

How strong was the patent estate?

Patent 7,323,195 had moderate formulation-estate strength during its term and limited current strength after expiration.

Strengths during the patent term

The patent combined several claim elements that could make design-around more difficult:

  • A defined botanical source class;
  • An isolated aqueous-soluble polymer;
  • Stomach protection;
  • Enteric coating or controlled release;
  • Multiple dosage forms;
  • Multiparticulate beads;
  • Specific coating chemistry;
  • Manufacturing aids such as magnesium stearate.

The independent claims were broader than a claim limited solely to Croton lechleri or a single commercial tablet. The inclusion of Calophyllum and other Croton species expanded the theoretical source coverage.

Weaknesses

The claims were composition claims with multiple cumulative limitations. A competitor could challenge one or more of the following:

  • Whether the material was “isolated”;
  • Whether it was “aqueous soluble”;
  • Whether the source was within the specified botanical genera;
  • Whether the formulation actually protected the polymer from the stomach;
  • Whether a release system was “controlled release”;
  • Whether the product contained the claimed enteric coating or bead structure.

The patent did not broadly cover every Croton lechleri extract, every proanthocyanidin polymer, or every use of crofelemer. Its scope depended on the intersection of active-material identity and gastrointestinal dosage-form design.

Does biosimilar risk apply to crofelemer?

No. Biosimilar regulation generally applies to biological products under the Public Health Service Act. Crofelemer is a small-molecule botanical drug product rather than a biologic subject to the biosimilar pathway.

A competing crofelemer product would generally be evaluated through a generic-drug pathway, potentially including an ANDA, rather than a biosimilar application. FDA approval would depend on the reference product, dosage form, active-ingredient characterization, bioequivalence requirements, and applicable regulatory exclusivity. (FDA, n.d.-b)

The botanical origin does create technical issues that may be more complex than those associated with a conventional synthetic small molecule. These can include:

  • Batch-to-batch polymer consistency;
  • Source-plant authentication;
  • Extraction and purification controls;
  • Molecular-weight distribution;
  • Analytical characterization;
  • Impurity and contaminant controls;
  • Stability of the finished dosage form.

Those issues are manufacturing and regulatory barriers, not continuing exclusivity rights under Patent 7,323,195.

What generic launch scenarios exist after expiration?

Three principal scenarios exist.

Immediate conventional generic entry

A manufacturer could seek approval for a crofelemer product with a formulation that matches the reference product’s dosage form and release characteristics. Because Patent 7,323,195 expired in 2022, that patent alone would not block launch.

Formulation redesign

A manufacturer could use a different enteric polymer, multiparticulate system, or controlled-release architecture. The expired patent would not prevent such development, but the design would still need to meet FDA performance and bioequivalence requirements.

Delayed or limited launch

Commercial entry could remain constrained by manufacturing complexity, limited market size, reference-product availability, or later patents. Those barriers would be separate from the expired claims of Patent 7,323,195.

What geographic coverage did the patent provide?

Patent 7,323,195 provided U.S. protection only. It did not directly protect the same formulation in Europe, Canada, Japan, Latin America, or other jurisdictions.

Foreign family members would require separate review for:

  • Filing dates;
  • National-phase status;
  • Grant status;
  • Local claim amendments;
  • Patent-term adjustments;
  • Supplementary protection certificates;
  • Local expiration dates;
  • Opposition or revocation proceedings.

Expiration of the U.S. patent does not establish freedom to operate internationally.

What licensing deals are relevant?

The patent sits within the commercial history of crofelemer, which involved rights and development activities associated with Shaman Pharmaceuticals, Napo Pharmaceuticals, and later commercial partners. The commercial rights to crofelemer have changed over time, but a license or collaboration agreement does not extend an expired patent term.

Licensing can still affect market access through:

  • Territory rights;
  • Manufacturing rights;
  • Supply obligations;
  • Know-how licenses;
  • Trademark rights;
  • Regulatory dossier access;
  • Royalty obligations;
  • Restrictions on use of proprietary botanical starting materials.

These contractual rights should be separated from the enforceability of U.S. Patent 7,323,195.

Key Takeaways

  • U.S. Patent 7,323,195 covers oral formulations containing an aqueous-soluble isolated proanthocyanidin polymer from Croton or Calophyllum species.
  • Croton lechleri is specifically covered by dependent claims 3 and 4.
  • Claim 1 focuses on enteric-coated formulations.
  • Claim 2 covers controlled-release oral preparations that protect the polymer from the stomach.
  • Dependent claims cover methacrylate enteric polymers, tablets, capsules, coated beads, granules, powders, and magnesium stearate.
  • The patent expired on May 11, 2022.
  • It was historically relevant to crofelemer formulations marketed as Fulyzaq and Mytesi.
  • The patent is no longer a current U.S. blocking right.
  • Crofelemer is not subject to biosimilar regulation; competing products would generally follow a generic-drug pathway.
  • Current commercial risk would arise from later patents, regulatory requirements, manufacturing know-how, supply arrangements, or market economics rather than this expired patent.

FAQs

Can a generic manufacturer use Croton lechleri after Patent 7,323,195 expired?

Yes, expiration of the patent removes the patent restriction on the claimed U.S. composition subject matter. FDA approval, product quality, manufacturing, and any later patent rights remain separate issues.

Does Patent 7,323,195 cover crofelemer as a chemical compound?

No. The claims focus on a pharmaceutical composition containing an isolated, aqueous-soluble proanthocyanidin polymer and a stomach-protective oral formulation.

Is an enteric coating mandatory for every claim?

No. Claim 1 expressly requires an enteric coating. Claim 2 instead requires a controlled-release oral preparation formulated to protect the polymer from the stomach environment.

Could a Calophyllum-derived polymer fall within the patent?

Yes. Claims 1 and 2 expressly include qualifying aqueous-soluble isolated proanthocyanidin polymer compositions from Calophyllum species.

Does expiration of the patent guarantee FDA approval of a crofelemer generic?

No. Patent expiration removes one intellectual-property barrier. FDA approval would still require compliance with applicable generic-drug, quality, bioequivalence, analytical, and manufacturing requirements.

References

Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/ob/

Food and Drug Administration. (n.d.-b). Generic drug facts. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts

Google Patents. (n.d.). U.S. Patent No. 7,323,195, pharmaceutical compositions comprising proanthocyanidin polymers. https://patents.google.com/

U.S. Patent No. 7,323,195. (2008). Pharmaceutical compositions comprising proanthocyanidin polymers. United States Patent and Trademark Office.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 7,323,195

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,323,195

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 430477 ⤷  Start Trial
Australia 2030302 ⤷  Start Trial
Australia 4988197 ⤷  Start Trial
Australia 775330 ⤷  Start Trial
Canada 2269078 ⤷  Start Trial
Germany 69739394 ⤷  Start Trial
Denmark 0935417 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.